Harvard Bioscience Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Harvard Bioscience de 98.9% y 7.2% por año respectivamente. Se prevé que el BPA crezca en un 99.1% al año. Se espera que la rentabilidad financiera sea de 7.8% en 3 años.
Información clave
106.7%
Tasa de crecimiento de los beneficios
107.4%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Life Sciences | 17.0% |
| Tasa de crecimiento de los ingresos | 9.3% |
| Rentabilidad financiera futura | 4.7% |
| Cobertura de analistas | Low |
| Última actualización | 08 May 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Even With A 25% Surge, Cautious Investors Are Not Rewarding Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Performance Completely
Dec 22
Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Intrinsic Value Is Potentially 60% Above Its Share Price
Sep 23Harvard Bioscience, Inc. (NASDAQ:HBIO) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aug 10An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 23% Undervalued
Apr 26Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Afford Some Debt
Apr 11Harvard Bioscience GAAP EPS of $0.05 beats by $0.06, revenue of $29.2M misses by $1.2M
Aug 04Harvard Bioscience (NASDAQ:HBIO) Takes On Some Risk With Its Use Of Debt
Jun 08Harvard Bioscience - Dressed Up And Waiting For A Suitor
Mar 15Here's Why Harvard Bioscience (NASDAQ:HBIO) Can Manage Its Debt Responsibly
Feb 16Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Nov 04Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Trading At A 37% Discount?
Oct 01An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 25% Undervalued
May 04These 4 Measures Indicate That Harvard Bioscience (NASDAQ:HBIO) Is Using Debt Extensively
Apr 19Analysts Are Optimistic We'll See A Profit From Harvard Bioscience, Inc. (NASDAQ:HBIO)
Apr 04Have Insiders Sold Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares Recently?
Mar 20What Kind Of Shareholders Hold The Majority In Harvard Bioscience, Inc.'s (NASDAQ:HBIO) Shares?
Mar 07Harvard Bioscience (NASDAQ:HBIO) Shareholders Have Enjoyed A 92% Share Price Gain
Feb 17An Intrinsic Calculation For Harvard Bioscience, Inc. (NASDAQ:HBIO) Suggests It's 35% Undervalued
Feb 02
Have Insiders Been Buying Harvard Bioscience, Inc. (NASDAQ:HBIO) Shares This Year?
Jan 15Harvard Bioscience: Wait For The Green Shoots Of Improvement
Jan 12When Will Harvard Bioscience, Inc. (NASDAQ:HBIO) Become Profitable?
Dec 28Is Harvard Bioscience (NASDAQ:HBIO) Using Too Much Debt?
Dec 11At US$3.78, Is Harvard Bioscience, Inc. (NASDAQ:HBIO) Worth Looking At Closely?
Nov 26Harvard Bioscience, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2026 | 138 | 7 | 13 | 17 | 1 |
| 12/31/2025 | 124 | 3 | 9 | 13 | 2 |
| 12/31/2024 | 112 | -4 | 5 | 8 | 2 |
| 3/31/2024 | 107 | -9 | 11 | 14 | N/A |
| 12/31/2023 | 112 | -3 | 12 | 14 | N/A |
| 9/30/2023 | 113 | -3 | 11 | 12 | N/A |
| 6/30/2023 | 114 | -5 | 7 | 9 | N/A |
| 3/31/2023 | 115 | -2 | 4 | 5 | N/A |
| 12/31/2022 | 113 | -10 | 0 | 1 | N/A |
| 9/30/2022 | 118 | -7 | -3 | -1 | N/A |
| 6/30/2022 | 121 | -4 | -4 | -3 | N/A |
| 3/31/2022 | 121 | -6 | -3 | -2 | N/A |
| 12/31/2021 | 119 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 117 | -2 | 2 | 4 | N/A |
| 6/30/2021 | 111 | -3 | 5 | 6 | N/A |
| 3/31/2021 | 105 | -4 | 6 | 7 | N/A |
| 12/31/2020 | 102 | -8 | 8 | 9 | N/A |
| 9/30/2020 | 102 | -7 | 8 | 9 | N/A |
| 6/30/2020 | 105 | -8 | 9 | 11 | N/A |
| 3/31/2020 | 112 | -7 | 8 | 9 | N/A |
| 12/31/2019 | 116 | -5 | 7 | 8 | N/A |
| 9/30/2019 | 119 | -2 | 8 | 8 | N/A |
| 6/30/2019 | 120 | 0 | 3 | 4 | N/A |
| 3/31/2019 | 122 | -1 | 4 | 4 | N/A |
| 12/31/2018 | 121 | -4 | 2 | 3 | N/A |
| 9/30/2018 | 109 | -8 | -2 | -1 | N/A |
| 6/30/2018 | 99 | -8 | 2 | 3 | N/A |
| 3/31/2018 | 86 | -7 | 1 | 2 | N/A |
| 12/31/2017 | 77 | -2 | N/A | 1 | N/A |
| 9/30/2017 | 82 | -3 | N/A | 4 | N/A |
| 6/30/2017 | 88 | -4 | N/A | 5 | N/A |
| 3/31/2017 | 96 | -4 | N/A | 5 | N/A |
| 12/31/2016 | 105 | -4 | N/A | 5 | N/A |
| 9/30/2016 | 106 | -20 | N/A | 5 | N/A |
| 6/30/2016 | 107 | -19 | N/A | 2 | N/A |
| 3/31/2016 | 110 | -18 | N/A | 0 | N/A |
| 12/31/2015 | 109 | -19 | N/A | 1 | N/A |
| 9/30/2015 | 111 | -2 | N/A | 0 | N/A |
| 6/30/2015 | 110 | 0 | N/A | 1 | N/A |
| 3/31/2015 | 109 | 0 | N/A | 3 | N/A |
| 12/31/2014 | 109 | 2 | N/A | 4 | N/A |
| 9/30/2014 | 106 | 2 | N/A | 4 | N/A |
| 6/30/2014 | 106 | 1 | N/A | 5 | N/A |
| 3/31/2014 | 105 | 1 | N/A | 5 | N/A |
| 12/31/2013 | 105 | 1 | N/A | 4 | N/A |
| 9/30/2013 | 106 | 4 | N/A | 4 | N/A |
| 6/30/2013 | 107 | 4 | N/A | 5 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que HBIO sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).
Beneficios vs. Mercado: Se prevé que HBIO sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que HBIO sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (9.7% al año) de HBIO crezcan más rápidamente que los del mercado US (8.3% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 7.2% al año) de HBIO crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de HBIO sea baja dentro de 3 años (7.8%).